Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.
US-headquartered small molecule drug developer Aligos Therapeutics went public on Friday in a $150m initial public offering representing an exit for pharmaceutical firms Roche and Novo. The company priced 10 million shares in the middle of the IPO’s $14 to $16 range. Its shares opened at $17.40 on the Nasdaq Global Select Market and closed…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.